The study found that many state economies are already highly dependent on the biopharmaceutical industry, including New Jersey, Massachusetts, Connecticut, California, New York, Pennsylvania, Rhode Island, North Carolina, Washington and Utah.
The state economies in Nevada, Vermont, Alabama, New Hampshire, Florida and West Virginia also show great potential for capitalizing on biopharmaceutical development in the next 10 years.
The Milken Institute’s report. State by state biopharma economic contributions.